Posts Archive

Multiple Myeloma Research Foundation - MMRF - Genomics | High Impact Topic (HIT) Genomics: Hear how doctors can use genomic information...

MCRT Webcast - Myeloma Crowd Round Table, May 8, 2021 Dana-Farber Cancer Institute Myeloma Crowd Round Tables program Treating Myeloma at...

REST NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST) Newly diagnosed multiple myeloma patients...

ClaSPd NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed...

NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients NCT04802356: Phase 2:...

Clinical Trials: Discover how clinical trials work. Multiple Myeloma Research Foundation - MMRF - Clinical Trials | High Impact Topic...

What is the MMRF CureCloud®? Welcome to the MMRF CureCloud! Multiple Myeloma Research Foundation - MMRF The MMRF CureCloud® is a...

American Cancer Society - www.cancer.org: What is CART Cell Therapy? CAR T-cell therapy Learn more: https://www.cancer.gov/publications/d...

NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients Study of FasT CAR-T GC012F Injection in High...

MCRT Webcast - Myeloma Crowd Round Table Myeloma Crowd Round Tables program MCRT Webcast Apr 24, 2021 The Role of Venetoclax in Myeloma -...

Multiple Myeloma Autologous Stem Cell Transplantation THE MMRF - Multiple Myeloma Autologous Stem Cell Transplantation Click here to read...

Multiple Myeloma Research Foundation - MMRF -Autologous Hematopoietic Stem Cell Transplantation ASCT Autologous Stem Cell Transplantation...

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma This study will assess...

What is a Clinical Trial? Clearing Up Common Misconceptions Are clinical trials only available if I have exhausted all other options? Am...

NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...

NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM As optimal...

What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria What are myeloma defining events? ...

NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (IMPEDE)...

NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies GEN3014 Safety Trial in Relapsed or...

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis NCT04754945: Phase 1: Isatuximab as...

NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM A...

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

Multiple Myeloma Research Foundation THE MMRF - The Path to Precision Medicine in Multiple Myeloma THE MMRF - The Path to Precision...

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Blood Cancer J; 2021...